Multi-source health news digests
A five-year randomised controlled trial published in the New England Journal of Medicine has confirmed that GLP-1 receptor agonists — the class of drugs that includes Ozempic and Wegovy — reduce major cardiovascular events by 20% in patients with obesity and type-2 diabetes, independent of their weight-loss effects. The findings, involving 23,000 participants across 40 countries, are expected to accelerate prescribing guidelines and may prompt health systems globally to broaden reimbursement eligibility.